<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2020000500036</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.19000329</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Translocación inusual t(2;11)(q31;p15) y FLT3-ITD en un paciente pedriátrico con leucemia mielomonocítica aguda]]></article-title>
<article-title xml:lang="en"><![CDATA[Inusual translocation t(2;11)(q31;p15) and FLT3-ITD in a pediatric patient with acute mylomonocytic leukemia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jarquín-Ramírez]]></surname>
<given-names><![CDATA[Berenice]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Martínez]]></surname>
<given-names><![CDATA[Elizabeth C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivera-Sánchez]]></surname>
<given-names><![CDATA[Netzi]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz-Gálvez]]></surname>
<given-names><![CDATA[Víctor M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar-Escobar]]></surname>
<given-names><![CDATA[Virginia D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vega-Vega]]></surname>
<given-names><![CDATA[María Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garay-Sánchez]]></surname>
<given-names><![CDATA[Sergio A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Infantil Teletón de Oncología Laboratorio de Genética molecular ]]></institution>
<addr-line><![CDATA[ Querétaro]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Infantil Teletón de Oncología Subdirección de Diagnóstico y Banco de sangre ]]></institution>
<addr-line><![CDATA[ Querétaro]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Infantil Teletón de Oncología Dirección General ]]></institution>
<addr-line><![CDATA[ Querétaro]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>19</volume>
<fpage>36</fpage>
<lpage>40</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2020000500036&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2020000500036&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2020000500036&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La leucemia mieloide aguda (LMA) es una enfermedad con proliferación anormal de células progenitoras mieloides y constituye el 15-20% de los casos de leucemia aguda en la población pediátrica. Paciente mexicana con LMA (FAB M4) que presentó cariotipo 46,XX,t(2;11)(q31;p15), duplicación FLT3-ITD detectada y expresión para CD34, CD13, CD65, CD11c y MPO por citometría de flujo. Este es el décimo caso descrito en la literatura internacional con la t(2;11)(q31;p15) y el primero que se asocia con mutación FLT3-ITD.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Acute myeloid leukemia (AML) is a disease with abnormal proliferation of myeloid progenitor cells. The frequency of acute leukemia in pediatric population is 15-20%. Mexican female patient with AML (FAB M4) who presented karyotype 46,XX,t(2;11)(q31;p15), detected FLT3-ITD duplication and expression for CD34, CD13, CD65, CD11c and MPO by flow cytometry. This case is the tenth in international literature with t(2;11)(q31;p15) and the first described in association with FLT3-ITD mutation.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Translocación Genética]]></kwd>
<kwd lng="es"><![CDATA[Leucemia Mieloide Aguda]]></kwd>
<kwd lng="es"><![CDATA[Tirosina cinasa 3 similar a fms]]></kwd>
<kwd lng="es"><![CDATA[Complejo Proteico Nucleoporina 98]]></kwd>
<kwd lng="es"><![CDATA[Humanos]]></kwd>
<kwd lng="es"><![CDATA[Cariotipo]]></kwd>
<kwd lng="en"><![CDATA[Translocation]]></kwd>
<kwd lng="en"><![CDATA[Genetic]]></kwd>
<kwd lng="en"><![CDATA[Leukemia]]></kwd>
<kwd lng="en"><![CDATA[Myeloid]]></kwd>
<kwd lng="en"><![CDATA[Acute]]></kwd>
<kwd lng="en"><![CDATA[Fms-Like Tyrosine Kinase 3]]></kwd>
<kwd lng="en"><![CDATA[Nuclear pore complex protein 98]]></kwd>
<kwd lng="en"><![CDATA[Humans]]></kwd>
<kwd lng="en"><![CDATA[Karyotype]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swerdlow]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Jaffe]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Pileri]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues]]></source>
<year>2017</year>
<volume>4</volume>
<publisher-loc><![CDATA[Lyon, Francia ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kok]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Perugini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iarossi]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[D'Andrea]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome:A combined analysis of 1053 core-binding factor AML patients]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2013</year>
<volume>160</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>557-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[L&#1094;ffler]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gassmann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Haferlach]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AML M1 and M2 with eosinophilia and AML M4Eo:diagnostic and clinical aspects]]></article-title>
<source><![CDATA[Leuk Lymphoma]]></source>
<year>1995</year>
<volume>18</volume>
<numero>suppl1</numero>
<issue>suppl1</issue>
<page-range>61-3</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marlton]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Keating]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kantarjian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pierce]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[O'Brien]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Freireich]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>1995</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>965-71</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kyo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Miwa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kamada]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kita]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heterogeneous fusion transcripts involving the NUP98 gene and HOXD13 gene activation in a case of acute myeloid leukemia with the t(2;11)(q31;p15) translocation]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2000</year>
<volume>14</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1621-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimada]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sekiguchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ishii]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tanitsu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sasaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Generation of the NUP98-HOXD13 fusion transcript by a rare translocation, t(2;11)(q31;p15), in a case of infant leukaemia]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2000</year>
<volume>110</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>210-3</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[t(2;11)(q31;p15) NUP98/HOXD13 - t(2;11)(q31;p15) NUP98/HOXD11]]></article-title>
<source><![CDATA[Atlas Genet Cytogenet Oncol Haematol]]></source>
<year>2013</year>
<volume>17</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>642-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kobzev]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Climent]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rowley]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of translocations that involve the NUP98 gene in patients with 11p15 chromosomal rearrangements]]></article-title>
<source><![CDATA[Genes Chromosom Cancer]]></source>
<year>2004</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>339-52</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Moon]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two concurrent chromosomal aberrations involving three-way t(3;21;8)(p21;q22;q22) and two-way t(2;11)(q31;p15) translocations in a case of de novo acute myeloid leukemia]]></article-title>
<source><![CDATA[Lab Med Online]]></source>
<year>2016</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>246</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhalla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[t(2;11)(q31;p15) in therapy related myeloid neoplasm:case report and review of literature]]></article-title>
<source><![CDATA[Atlas Genet Cytogenet Oncol Haematol]]></source>
<year>2013</year>
<volume>17</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>866-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sexauer]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Tasian]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting FLT3 signaling in childhood acute myeloid leukemia]]></article-title>
<source><![CDATA[Front Pediatr]]></source>
<year>2017</year>
<volume>5</volume>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Hafez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay]]></article-title>
<source><![CDATA[J Mol Diagnostics]]></source>
<year>2003</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>96-102</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rombouts]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Blokland]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lowenberg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ploemacher]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2000</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>675-83</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kottaridis]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Gale]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Frew]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Langabeer]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Belton]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy :analysis of 854 trials from the United Kingdom Medical Research Council AML 10 and 12 trials]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2001</year>
<volume>98</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1752-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilliland]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The roles of FLT3 in hematopoiesis and leukemia]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2002</year>
<volume>100</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1532-42</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taketani]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Taki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shibuya]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15)]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2002</year>
<volume>62</volume>
<page-range>33-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hidaka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ishikawa-Matsumura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamauchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sano]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A complex karyotype, including a three-way translocation generating a NUP98-HOXD13 transcript, in an infant with acute myeloid leukemia]]></article-title>
<source><![CDATA[Cancer Genet Cytogenet]]></source>
<year>2007</year>
<volume>176</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>137-43</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emerenciano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[MacEdo-Silva]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[De Meis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dobbin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Marschalek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Backtracking to birth of the NUP98-HOXD13 gene fusion in an infant acute myeloid leukemia]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2011</year>
<volume>25</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1192-4</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raza-Egilmez]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shows]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Aplan]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Grossi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jani-Sait]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1998</year>
<volume>58</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>4269-73</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmqvist]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Argiropoulos]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pineault]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Abramovich]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sly]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Krystal]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2006</year>
<volume>108</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1030-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hara]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shiba]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ohki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shimada]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tomizawa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poor prognosis associated with FAB subtypes M4 and M5 in Japanese pediatric acute myeloid leukemia patients with FLT3-ITD]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2014</year>
<volume>124</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>1002-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
